Recent Updates — CUPR
Cuprina Holdings (Cayman) Limited shareholders approved an increase in the company's authorized share capital from US$100,000 divided into 12.5 million ordinary shares to US$10 million divided into 1.25 billion ordinary shares at an extraordinary general meeting on October 15, 2026. The vote also approved the adoption of the Third Amended and Restated Memorandum and Articles of Association to reflect this capital increase and adjust thresholds for ordinary resolutions in writing. Cuprina Holdings operates as a holding company.
Cuprina Holdings (Cayman) Limited announced the acquisition of East Coast Podiatry Centre Pte. Ltd. and Orchard Clinic Management Pte. Ltd., which operate podiatry and women's health clinics in Singapore, for approximately S$4.0 million (US$3.1 million). The Target Group reported FY2025 unaudited revenue of S$9.1 million and normalized EBITDA of S$1.2 million. Consideration includes S$3.0 million in cash and S$1.0 million paid via 301,671 Class A ordinary shares issued at a derived price of S$3.31 per share. Completion is expected by November 1, 2026, subject to shareholder approval for an authorized share capital increase. This strategic move integrates clinical platforms with Cuprina's wound-care and collagen technologies.
Cuprina Holdings (Cayman) Limited closed its public offering by fully exercising the underwriter's over-allotment option on September 29, 2026. The company issued and sold an additional 648,373 Class A ordinary shares at a price of $1.15 per share, generating approximately $745,629 in gross proceeds. This brings the aggregate gross proceeds from the offering to approximately $5,716,491, prior to deducting underwriting discounts and expenses. The company also issued warrants to purchase 25,935 shares to the representative of the underwriters at an exercise price of $1.265 per share. Cuprina Holdings is a biomedical and biotechnology company developing products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals.
Cuprina Holdings (Cayman) Limited is soliciting shareholder approval at its Extraordinary General Meeting on October 15, 2026, to increase its authorized share capital from US$100,000 divided into 12.5 million shares to US$10,000,000 divided into 1.25 billion shares. The company also seeks approval to adopt a Third Amended and Restated Memorandum and Articles of Association reflecting this increase and lowering the threshold for ordinary resolutions in writing to a simple majority. These changes are intended to provide transactional flexibility for basic financing needs and potential business development. Cuprina Holdings (Cayman) Limited operates as an investment holding company.
Cuprina Holdings (Cayman) Limited closed a public offering of 4,322,489 Class A Ordinary Shares at $1.15 per share on September 17, 2026, generating approximately $4.97 million in gross proceeds before expenses. The company granted the underwriter a 45-day option to purchase up to an additional 648,373 shares via over-allotment, which would increase gross proceeds to roughly $5.72 million. Additionally, Cuprina issued warrants to R. F. Lafferty & Co., Inc. to purchase 172,900 Class A Ordinary Shares at an exercise price of $1.265 per share. Net proceeds are intended for business expansion, research and development, market growth, infrastructure investment, and working capital. Cuprina Holdings (Cayman) Limited is a biomedical company developing and marketing products for chronic wounds, infertility, medical waste recycling, and cosmeceuticals.
Cuprina Holdings (Cayman) Limited announced on June 15, 2026, that it received clearance from the U.S. Food and Drug Administration (FDA) for its MEDIFLY Maggots product. The company operates in the biotechnology industry, focusing on medical applications.